Profile data is unavailable for this security.
About the company
TSUMURA & CO. is a Japan-based company mainly engaged in the manufacture and sale of ethical and general pharmaceuticals. Through its subsidiaries, the Company is also engaged in the procurement, sorting and processing of crude drugs, the manufacture and sale of Chinese herbal extract powders and drug substances, the operation of dispensing pharmacies and the provision of logistics services, as well as the development of pharmaceuticals.
- Revenue in JPY (TTM)157.50bn
- Net income in JPY23.56bn
- Incorporated1936
- Employees4.14k
- LocationTsumura & Co2-17-11, AkasakaMINATO-KU 107-8521JapanJPN
- Phone+81 363617200
- Websitehttps://www.tsumura.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liaoning Cheng Da Co Ltd | 241.22bn | 7.40bn | 368.88bn | 3.36k | 49.79 | 0.5846 | -- | 1.53 | 0.2268 | 0.2268 | 7.42 | 19.31 | 0.2371 | 5.28 | 5.77 | 3,365,262.00 | 0.2322 | 3.59 | 0.3297 | 5.21 | 13.90 | 14.15 | 0.9793 | 9.89 | 0.9129 | -- | 0.2831 | 15.93 | -25.97 | -10.97 | -80.95 | -21.26 | 7.04 | -- |
| China Medical System Holdings Ltd | 149.52bn | 29.64bn | 374.08bn | 5.78k | 12.64 | 1.09 | 10.89 | 2.50 | 0.6202 | 0.6202 | 3.13 | 7.18 | 0.384 | 2.89 | 5.65 | 1,340,942.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| Hisamitsu Pharmaceutical Co Inc | 150.19bn | 14.65bn | 375.07bn | 2.76k | 22.56 | 1.18 | 17.99 | 2.50 | 195.20 | 195.20 | 1,996.17 | 3,730.09 | 0.4323 | 3.01 | 3.22 | 54,434,580.00 | 4.36 | 4.22 | 5.25 | 4.82 | 56.42 | 58.62 | 10.10 | 10.03 | 3.14 | -- | 0.004 | 53.05 | 10.42 | -0.2385 | 18.97 | -6.17 | 28.90 | 0.5989 |
| Amphastar Pharmaceuticals Inc | 108.38bn | 25.32bn | 375.79bn | 1.76k | 16.18 | 3.49 | 11.26 | 3.47 | 3.14 | 3.14 | 13.45 | 14.57 | 0.4968 | 2.85 | 6.04 | 404,821.70 | 11.71 | 9.42 | 13.54 | 11.56 | 54.68 | 47.83 | 23.56 | 15.23 | 2.63 | 7.42 | 0.4515 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 298.63bn | 62.00bn | 379.56bn | 15.00k | 6.12 | 1.32 | 5.12 | 1.27 | 1.74 | 1.74 | 8.40 | 8.11 | 0.6578 | 3.30 | 5.67 | 1,017,893.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| Bavarian Nordic A/S | 134.94bn | 15.69bn | 382.65bn | 1.38k | 24.16 | 1.64 | 13.22 | 2.84 | 9.06 | 9.06 | 78.44 | 133.68 | 0.4157 | 1.50 | 5.10 | 4,410,899.00 | 4.83 | 1.21 | 6.24 | 1.48 | 56.91 | 53.72 | 11.63 | 4.06 | 0.9311 | -- | 0.0118 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Twist Bioscience Corp | 44.88bn | -33.50bn | 384.61bn | 919.00 | -- | 5.14 | -- | 8.57 | -3.81 | -3.81 | 5.12 | 8.39 | 0.4076 | 5.42 | 8.56 | 321,229.60 | -30.42 | -30.50 | -33.85 | -33.84 | 40.53 | 36.02 | -74.63 | -113.33 | 4.52 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Alembic Pharmaceuticals Ltd | 113.98bn | 11.39bn | 385.09bn | 14.86k | 33.82 | -- | 23.53 | 3.38 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Catalyst Pharmaceuticals Inc | 66.06bn | 10.36bn | 389.04bn | 167.00 | 40.41 | 4.20 | 24.43 | 5.89 | 0.5335 | 0.5335 | 3.71 | 5.14 | 0.7554 | 4.03 | 8.69 | 2,601,647.00 | 11.85 | 25.42 | 13.56 | 29.81 | 86.67 | 85.63 | 15.69 | 30.87 | 4.94 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Tsumura & Co | 157.50bn | 23.56bn | 389.16bn | 4.14k | 16.35 | 1.37 | 10.79 | 2.47 | 310.18 | 310.18 | 2,073.96 | 3,712.37 | 0.3703 | 0.7043 | 2.29 | 38,061,620.00 | 5.90 | 4.81 | 7.39 | 5.89 | 47.59 | 50.98 | 15.94 | 12.65 | 2.31 | -- | 0.2058 | 32.16 | 7.71 | 4.52 | 1.37 | 2.74 | 17.54 | 5.84 |
| Shandong Buchang Pharmaceuticals Co Ltd | 251.53bn | -6.26bn | 399.24bn | 8.31k | -- | 1.67 | -- | 1.59 | -0.2619 | -0.2619 | 10.76 | 10.09 | 0.5777 | 1.08 | 9.78 | 1,416,955.00 | -2.26 | 3.26 | -3.13 | 4.72 | 58.25 | 74.71 | -3.92 | 4.85 | 0.5070 | 0.1602 | 0.2675 | 121.01 | -11.41 | -0.6219 | 120.85 | -29.93 | -16.56 | -36.72 |
| Hypera SA | 210.17bn | 44.48bn | 401.00bn | 9.00k | 9.08 | 1.27 | 7.83 | 1.91 | 2.65 | 2.65 | 12.54 | 19.00 | 0.3254 | 1.44 | 2.76 | -- | 6.88 | 8.29 | 8.35 | 9.98 | 61.86 | 63.49 | 21.13 | 26.01 | 1.46 | -- | 0.4637 | 50.18 | 4.88 | 16.27 | -3.30 | 7.74 | 29.83 | 10.24 |
Data as of Nov 01 2024. Currency figures normalised to Tsumura & Co's reporting currency: Japanese Yen JPY
29.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Marathon Asset Management Ltd.as of 29 Mar 2024 | 5.59m | 7.29% |
| Nomura Asset Management Co., Ltd.as of 30 Sep 2024 | 4.00m | 5.21% |
| Invesco Asset Management (Japan) Ltd.as of 15 Aug 2024 | 3.38m | 4.40% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Apr 2024 | 2.52m | 3.29% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 2.19m | 2.85% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.25m | 1.63% |
| Templeton Investment Counsel LLCas of 30 Sep 2024 | 1.19m | 1.55% |
| Baillie Gifford & Co.as of 30 Sep 2024 | 972.80k | 1.27% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 970.10k | 1.26% |
| Nikko Asset Management Co., Ltd.as of 15 Apr 2024 | 938.80k | 1.22% |
More ▼
Data from 30 Jun 2024 - 24 Oct 2024Source: FactSet Research Systems Inc.
